PTC Therapeutics profit margin PTCT

Gross, operating and net profit as a share of revenue over the last twelve months, from 2012.

Net margin, 12 months: −3.8%
Operating margin, 12 months: 12.5%
Net margin on a year earlier: −39.5 pts
Peer median: 18.1%

Over the twelve months to Jun 30, 2026, PTC Therapeutics kept −3.8% of its revenue as net profit, with an operating margin of 12.5%.

Five years earlier its net margin was −82.9%.

The median for 10 large drugmakers of a similar size is 18.1%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal year	Net margin	Operating margin	Gross margin
FY2025	39.4%	50.1%	n/a
FY2024	−45.0%	−37.5%	n/a
FY2023	−66.8%	−46.9%	n/a
FY2022	−80.0%	−64.0%	n/a
FY2021	−97.3%	−69.5%	n/a
FY2020	n/a	n/a	n/a
FY2019	−82.0%	−78.6%	96.0%
FY2018	−48.4%	−43.7%	95.2%
FY2017	−40.6%	−33.1%	97.5%
FY2016	n/a	n/a	100.0%
FY2015	n/a	n/a	n/a
FY2014	n/a	n/a	n/a
FY2013	n/a	n/a	n/a
FY2012	−77.3%	−79.0%	n/a

Quarter by quarter

Quarter	Ended	Net margin, 12 months	Change on a year	Operating margin
Q2 FY26	Jun 30, 2026	−3.8%	−39.5 pts	12.5%
Q1 FY26	Mar 31, 2026	−22.6%	−56.1 pts	−7.1%
Q4 FY25	Dec 31, 2025	39.4%	+84.5 pts	50.1%
Q3 FY25	Sep 30, 2025	42.3%	+92.6 pts	43.6%
Q2 FY25	Jun 30, 2025	35.6%	+88.9 pts	40.7%
Q1 FY25	Mar 31, 2025	33.6%	+96.0 pts	40.2%
Q4 FY24	Dec 31, 2024	−45.0%	+21.8 pts	−37.5%
Q3 FY24	Sep 30, 2024	−50.3%	+30.1 pts	−14.9%
Q2 FY24	Jun 30, 2024	−53.3%	+22.2 pts	−22.0%
Q1 FY24	Mar 31, 2024	−62.4%	+11.7 pts	−39.6%
Q4 FY23	Dec 31, 2023	−66.8%	+13.2 pts	−46.9%
Q3 FY23	Sep 30, 2023	−80.4%	−4.1 pts	−80.9%

Against its peers

Companies in Drug Manufacturers - General nearest PTC Therapeutics' size, closest first, today.

Company	Profit margin
PTCTPTC Therapeutics	−3.8%
KNSAKiniksa Pharmaceuticals International	9.6%
LGNDLigand Pharmaceuticals	67.9%
INDVIndivior Pharmaceuticals	26.7%
AMRXAmneal Pharmaceuticals	5.0%
ARQTArcutis Biotherapeutics	6.1%
LQDALiquidia	30.7%
OGNOrganon	3.4%
ALKSAlkermes plc.	4.0%
TGTXTG Therapeutics	55.2%
PTGXProtagonist Therapeutics	29.4%
Peer median	18.1%

Where PTC Therapeutics ranks

#40of 84Large drugmakers with the highest profit margins

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on PTC Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.